While the use of enzymes as biocatalysts to assist in the industrial manufacture of fine chemicals and pharmaceuticals has enormous potential, application is frequently limited by evolution-led catalyst traits. The advent of designer biocatalysts, produced by informed selection and mutation through recombinant DNA technology, enables production of process-compatible enzymes. However, to fully realize the potential of designer enzymes in industrial applications, it will be necessary to tailor catalyst properties so that they are optimal not only for a given reaction but also in the context of the industrial process in which the enzyme is applied.
Ideal processes
Bioprocess engineers develop processes not only against fixed capital and operating expenditure, but also rapid, and often, very aggressive timelines. This is particularly the case for pharmaceutical products where patent expiry on the product demands a robust and scalable process with short development times 12 . Conventionally, once a synthetic route is fixed and the biocatalytic step defined, bioprocess design and operation are centered on the properties of the biocatalyst. There are two reasons for this. First, biocatalysts are typically characterized by tight operational specifications. Second, the biocatalyst can often represent a significant proportion of the process operating costs. Increasingly, with more expensive substrates and improved biocatalyst production this contributing proportion is being reduced, and with expansion of the range of suitable biocatalysts, it may become desirable as well as possible to center bioprocess design and operation on the reaction properties, rather than the biocatalyst (see Fig. 1 ). Thus, the conventional paradigm can be reversed and the biocatalyst can be designed to fit the process. This alternative approach leads us to ask: what are the ideal properties we would want of a "designer" biocatalyst, and how would we identify these ideal properties?
The flexibility to design the biocatalyst to fit the process still carries a number of catalyst-independent constraints, set by the thermodynamics of the reaction and the properties of reactants and products (Table 1 ). In particular, the water solubility characteristics of the reactants and products determine the medium for operation 13 , and their stability as a function of pH and temperature determine the range in which the process must operate. In addition, high product concentrations are important in optimizing product recovery.
Under the ideal process paradigm ( Fig. 1) , preselection of optimal process conditions can supersede the constraints of any particular biocatalyst. A range of technologies contributes to the preselection process (Fig. 2) . Having selected the "ideal" process conditions, a growing range of molecular technologies are available for identification or engineering of the "ideal" biocatalyst.
Catalyst production
The key to the process architecture defined in a particular case is whether the catalyst is to be used as a whole cell or an isolated enzyme. For the majority of enzyme-catalyzed reactions, use of an isolated (immobilized) enzyme is the ideal provided that isolation is simple. However, for membrane-bound and/or cofactor-dependent enzymes and/or those that are multiprotein complexes, isolation may not be possible, and here the alternative whole-cell process will prove the preferred option. It is beyond the scope of this review to consider in depth the presentation of the enzyme within a reaction system and the very important aspects of free versus cell-encapsulated biocatalysts, but the reader is directed to a number of relevant publications [14] [15] [16] .
Whether a whole-cell or an isolated-enzyme biocatalyst is required, expression in a rapidly growing, robust host is the first requirement. Constitutive, rather than inducible, expression is preferred. High lev- els of expression will minimize the fermentation volume, but may lead to inclusion body formation. Developments in host-vector systems, coupled with highly evolved fermentation technologies, have resulted in bacterial and fungal fermentations capable of yielding recombinant enzymes at levels of upward of 10 g/L, in stark comparison with laboratory-based expression of recombinant enzymes, where yields of 10-100 mg/L are frequently reported. In all cases, the cost of media imposes a need to minimize fermentation volumes by high levels of expression. Protease activities, which can result in substantial loss of biocatalyst yield, also need to be minimized.
Reactors
Ideal reactors are those with high space/time yield to reduce the capital costs. A packed bed of immobilized enzyme has clear advantages in that the voidage is low: 34% compared with up to over 80-90% for a stirred-tank reactor 17 . The hydrodynamics of a packed-bed reactor, characterized by plug flow, have a number of implications, particularly in the generation of concentration gradients of substrate and product. As a consequence, both low enzyme K M and substrate inhibition are critical, so as to capitalize on the concentration gradient generated from column input to output. Similarly, pH adjustment is not possible during a single pass through a packed bed, so it is essential that the pH/activity profile for the enzyme is sufficiently broad to accommodate any pH changes. Critically, multiphasic mixtures cannot be handled in a packed bed, although a fluidized bed is a reasonable compromise (S. Beveridge et al., unpublished data).
Product recovery
The ideal process involves the minimum number of downstream steps. The catalyst must be easily recovered (immobilization by retention inside the packed bed is optimal). A bottleneck for many current processes is the large volume of water from which the product must be removed, necessitating a concentration step before isolation 18 .
In the ideal process, the catalyst would withstand concentrations of the product high enough to allow a single isolation step without prior product concentration.
Key biocatalyst properties
Turnover. Considering that the primary objective of any industrial biotransformation process is a high degree of substrate conversion to product in the minimum possible time, the turnover of an enzyme represents a key factor in the concept of the ideal biocatalyst. As many enzymes have evolved for very specific and selective metabolic roles, the intrinsic activity or turnover of native enzymes depends fundamentally on the nature and mechanism of the in vivo reaction catalyzed and the position of in vivo reaction equilibria with respect to metabolic flux. Thus, a particular enzyme may catalyze a desired bioconversion reaction, but with a k cat too low for practical application, in which case improvement of the turnover using the novel technologies now available (e.g., directed evolution, gene shuffling, and combinations of rational and combinatorial methods) may be required 19 . 
Table 1. Constraints influencing the operating conditions of bioconversion processes
Type of constraint Description Reaction-specific constraints dependent on the Water solubility of reactants and products nature of reactants and products (which is dependent on pH and temperature) Stability of reactants and products Chemical nature of reactants and products Production or consumption of gases Production or consumption of acid or alkali Reaction equilibrium (which is in turn dependent on pH and temperature)
Biocatalyst-specific constraints dependent on the The pH range over which optimal activity and stability evolved or modified properties of the biocatalyst of biocatalyst can be maintained Temperature range for biocatalyst optimal activity and stability Concentration range of reactants/products that can be tolerated by biocatalyst without inhibition or saturation effects Figure 1 . The paradigm shift? Traditionally, the characteristics of the enzyme have constrained the operational limits of the process. New approaches to enzyme discovery offer the prospect of designing the biocatalyst to suit the optimal parameters of the process.
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REVIEW enzymes typically used in bioconversions vary widely, high turnovers are characteristic of most current commercial biocatalytic processes.
In an operational biocatalyst, the turnover may be influenced not only by the genetically determined functional capacity of the protein, but also by the microenvironment of the enzyme, and specifically by the form in which the biocatalyst is formulated and applied. Thus process conditions (e.g., the type and use of immobilized enzymes) have considerable influence over the maximum achievable turnover exhibited by the biocatalyst. Such chemical modifications frequently result in lowering of k cat values, attributed to a range of effects, including variations in protein flexibility and allosteric properties (conformational), decreased accessibility to the enzyme active site 20 (steric), and changes in the enzyme microenvironment by the selective attraction or exclusion of water, ions, solutes, and so on 21 .
The operating temperature of a biocatalytic process is frequently dictated by factors relating to the reaction rather than the catalyst, such as substrate/product solubilities, reagent stabilities, or the need to reduce undesirable side reactions. Arrhenius kinetics suggest that the highest feasible reaction temperature should be selected, but such selection is always constrained by biocatalyst stability. 
Fortunately, evolution has provided a relatively wide thermal range of native biocatalysts, and enzymes derived from psychrotolerant (cold-active) to hyperthermophilic microorganisms may retain high levels of activity and/or stability across a temperature range from below 10°C to around 100°C, as demonstrated for a set of functionally homologous enzymes in Figure 3 . Where the reaction temperature is dictated by the process components, a priori selection of an enzyme from the appropriate thermal group (Fig. 3 ) may minimize subsequent requirements for enhancing either turnover or molecular stability.
The ideal biocatalyst for bioconversions involving organic and hydrophobic substrates would exhibit high turnover in organic or aqueous-organic media. Many enzymes remain active and stable in organic media, but relatively few exhibit enhanced turnover. Although research using native enzymes has provided insight into the effects of solvents and ionic conditions on enzyme activity 22, 23 and control over reaction pathways 24 , biocatalysts with significantly improved turnover in organic solvent media have recently been developed ( Table 2) .
Selectivity. Substrate selectivity and affinity are evolved properties of an enzyme, related specifically to its metabolic role. For instance, the substrate range for highly specialized mammalian enzymes may be far narrower than that of extracellular fungal enzymes. In certain cases, broad substrate specificity is essential, as in the use of proteolytic and lipolytic enzymes in laundry detergents, whereas in the production of most pharmaceuticals and fine chemicals, strict substrate selectivity is required to ensure fidelity in the reaction pathway, and viable conversion yields.
Control and optimization of stereoselectivity in synthetic biotransformations and chiral resolutions have been seminal focus areas in biocatalysis in recent years, largely as a result of the inefficiency of conventional methods for stereochemical control. Many highly stereoselective biocatalysts are already in large-scale industrial use (see Table 3 ), and novel molecular genetic techniques have provided routes to further improved enantioselectivity, particularly in the hydrolase enzyme group (Table 4) .
Manipulation of substrate selectivity through similar molecular techniques has progressed to the point where the functionality of a biocatalyst can be transformed from one reaction type to another, for example, in the modification of indole-3-glycerophosphate synthase, by a combination of rational design and directed evolution, to produce novel phosphoribosyl anthranilate isomerase activity 25 . Substrate selectivity can readily be altered, using molecular or reaction engineering methods, to the extent where compounds of very different steric structure and chemical nature from the natural substrates can be efficiently converted by the biocatalyst . For instance, the D-selectivity of a native hydantoinase was reversed by mutagenesis and selective screening procedures, giving an L-specific enzyme with no equivalent in nature, able to catalyze the production of L-methionine 26 . Gene-shuffling techniques have been used to randomly recombine genes from two organisms possessing biphenyl dioxygenase activity, yielding a recombinant enzyme capable of oxidative degradation of polychlorinated biphenyls (PCBs) and simple aromatic monomers 27 .
Molecular stability. Biocatalyst stability is a major concern in virtually all bioprocesses, because it may affect process economics at a number of levels. Poor biocatalyst stability will result in longer process operations (resulting from decreasing catalytic efficiency), increased frequency of catalyst replacement and reduced product yields. The causes of reduced biocatalyst stability are intimately associated with the process conditions, and may include extremes of temperature, ionic strength, or pH that are outside the operating "stability window" of the catalyst, or the presence of denaturants, such as substrates/products, organic solvents, surfaces, or interfaces. Some of the options currently available to the bioprocess industry to address the problem of biocatalyst stability are summarized in Table 1 .
The effect of any deleterious condition on the lifespan of a biocatalyst is dependent first on the intrinsic molecular stability of the protein, and second on the mode of presentation of the enzyme in the reactor system (e.g., whether the enzyme is cell-encapsulated, immobilized, or crosslinked). Intrinsic molecular stability is a function of both amino acid sequence and tertiary (and quaternary) structure and is dictated, at least in part, by the origins of the protein. Studies of extremophilic organisms and their enzymes have provided extensive insights into both the outer limits of molecular stability and molecular mechanisms responsible for structural stabilization. Proteins of extremely high thermal stability (e.g., T m values of 80°-130°C) are typically isolated from hyperthermophilic organisms (growing at up to 115°C), whereas the proteins of psychrophilic organisms (growing to well below 0°C) are generally relatively unstable (e.g., T m values of 20°-50°C). While the selection of a hyperthermophile-derived biocatalyst provides a ready means of ensuring high molecular stability, such enzymes have evolved to function optimally at near the organism's growth temperature and exhibit reduced catalytic rates if employed at lower temperatures (see Fig. 3 ).
Over two decades of intensive study into the mechanisms of protein stability have led both to the identification of a range of molecular stabilization mechanisms (e.g., the presence of salt-bridging networks: see reviews [28] [29] [30] ) and to the engineering of increased structural stability by random and site-specific mutagenesis, enzyme evolu- 
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Product recovery REVIEW tion, and gene shuffling. While small increments in enzyme stability are typically achieved by site-specific mutagenesis 31 , some remarkable increases (T m values enhanced by 10°-15°C) have been achieved by directed enzyme evolution 32, 33 . Such changes are not always to the detriment of catalytic activity. For example, the engineering of a 340-fold increase in stability at 100°C in a Bacillus stearothermophilus protease by eight site-specific mutations 34 was achieved without compromising catalytic activity, contradicting the dogma that molecular stability and activity are reciprocally related (through global conformational flexibility). Furthermore, there is good evidence for a general correlation between molecular stability to temperature and to other denaturing conditions 35, 36 , suggesting common initiators and/or pathways of protein denaturation, whether induced by high temperature, extremes of pH, or the presence of organic solvents or detergents. The practical consequence of this observation is that the selection of a more thermostable enzyme variant (e.g., derived from a thermophilic source) or the engineering of enhanced thermostability may also result in increased molecular resistance to a range of deleterious conditions. Virtually all the industrially significant changes in catalyst stability (e.g., in the evolution of xylose isomerases in the glucose conversion/high-fructose syrup industry) have come from strain selection, chemical modification (immobilization, chemical crosslinking), classical mutagenesis, or random mutagenesis. Of these, chemical modification is still the most widely used technology in industry for increasing biocatalyst stability. This preoccupation with traditional technology may reflect the simplicity and reliability of the procedures, and their cost-effectiveness in comparison with more modern and sophisticated genetic technologies. Recent developments in immobilization and related technologies, including cell-surface expression of enzymes 37, 38 , multipoint covalent immobilization 39 , and the application of crosslinked enzyme crystals 40 , are likely to ensure that industrial biocatalysis continues to employ such methods. The last two of these methods take advantage of the fact that a restriction of conformational flexibility, as in covalent crosslinking or embedding in a crystal lattice, significantly increases the activation energy of denaturation and prevents enzyme aggregation.
Catalyst diversity
Whether a process is designed around the catalyst properties, or the catalyst is selected to suit process needs, the available range of relevant catalysts is a key issue. The range of enzymes potentially available to the bioprocess industry is firstly dictated by evolution, that is, by genetic diversity. Although little consensus exists on true genetic diversity (genetic represented as species diversity), estimates for plant, animal, and microbial diversity (see Table 5 ) are in the order of 10 7 -10 8 species. With an average of 10 4 -10 5 open reading frames per genome, many of which encode enzymes, the total enzyme genetic diversity may be as great as 10 13 distinct functional sequences. This figure is, of course, substantially reduced by the varying, often high, homology between enzymes from related and even unrelated organisms.
This diversity of closely, distantly, or unrelated sequences represents the core biological resource, conceptually considered in terms of "sequence space" 41 . Native sequence space, representing the diversity of functional (and nonfunctional) protein sequences available from nature, still represents a relatively small proportion of total sequence space-theoretically estimated as the total number of permutations of 20 amino acids (which is 20 100 for a polypeptide of 100 amino acids). Only a relatively small proportion of native sequence space is currently available to the scientific and bioindustrial community, for the simple reason that a very high proportion of extant species have never been investigated, or, even if investigated, are not readily accessible. The acknowledged reality that a very high proportion of microbial species are currently "unculturable" 42 (Table 5) Increased turnover Solubilization of enzyme Solubilization of subtilisin Specificity constant k cat /K M of solubilized (using isooctane + AOT a ) for subtilisin in octane = 10 3 × that of suspended application in organic solvents enzyme, and 0.1× that in aqueous medium; stability in octane 10 3 × > in aqueous medium 2 Biocatalyst plastics using Incorporation of chymotrypsin and subtilisin in chymotrypsin and subtilisin synthetic polymers gave 10 4 × increased reaction rates with high stability, in polar solvents, facilitating efficient peptide synthesis 58 Solubilization of chymotrypsin Activity of chymotrypsin and subtilisin and subtilisin for use in organic Carlsberg 10 3 greater than freeze-dried powder solvents using propanol rinsing and comparable with CLEC preparation 59 treatment
Molecular imprinting
Imprinting of subtilisin Acylation of thymidine by subtilisin in THF a with (Carlsberg and mutants) with 50× rate enhancement compared with nonsucrose, thymidine, and other imprinted enzyme. Substrate specificity altered nucleosides and reactivity improved (50-180× enhancement) with alternative nucleosides as substrates, by imprinting with similar nucleophiles 60 Induction of enzyme activity by Papain and lactoglobulin imprinted with a lyophilization of papain and transition-state analog showed activity in lactoglobulin in presence of the catalysis of β-elimination reactions 3× higher transition-state analog than nonimprinted protein 61 Altered Directed evolution Improved enantioselectivity in Pseudomonas aeruginosa lipase activity with enantioselectivity a lipases improved S-enantioselectivity; 2% ee increased to 81% ee after four generations of mutants 62 Reversed 25, 64 Rational design Desaturase altered to Change of activity from double-bond insertion to hydroxylase hydroxylation in oleate desaturase, by sitedirected mutagenesis at seven sites, selected by comparative analysis of amino acid sequences of oleate desaturases and unrelated hydroxylases 65 Gene shuffling and Modified β-galactosidase DNA shuffling gave an evolved β-galactosidase screening activity with 10-fold increased fucosidase and 40-fold less galactosidase activity, due to six amino acid changes 66 Conversion of nonDirected evolution Recombination to alter substrate Genes for biphenyl oxygenase activity from natural substrates specificity Pseudomonas pseudoalcaligenes and Burkholderia cepacia, with different substrate specificities, recombined to give dioxygenase activity for efficient PCB conversion 27 Increased enzyme Directed evolution Thermostable esterase developed Improved thermostability (>14°C increase in T m stability by directed evolution after six cycles of mutation) without loss of activity, showing that the two properties are not mutually exclusive 33 REVIEW sequence space (Fig. 4) . Chemical, site-directed, and random mutagenesis technologies access regions proximal to the native sequences, whereas methods, such as gene and domain swapping, DNA shuffling, and other forms of combinatorial genomics access the regions between the parent sequences.
Modern bioprospecting methods such as multiplex or metagenome cloning [43] [44] [45] [46] and similar methods used by companies such as Diversa Corporation (La Jolla, CA) and TerraGen Discovery (Vancouver, BC, Canada) directly access environmental genomes (whether culturable or unculturable). These methods access sequence space in a virtually random manner and have been successfully employed to isolate novel nahR (ref. 45 ) and amylase, lipase, and hemolytic enzyme genes 46 .
Perspective
If we accept the new paradigm that the design of an optimized process may proceed without intimate consideration of the limitations of the biocatalyst, and that technologies are available for the subsequent selection or design of the "ideal" catalyst, the following questions are highly relevant: First, where are the limiting factors? And second, what more is required to overcome the limiting factors?
It is evident from the recent literature that in vitro enzyme evolution technologies are being very rapidly assimilated. These offer a relatively fast and inexpensive approach to the incremental modification of selected enzyme properties, with a reduced risk that desirable enzyme characteristics will be lost in the process.
A major limitation is the monoselective nature of almost all protein-engineering and enzyme-screening technologies. Single-function screening is essentially incompatible with the requirements of the "ideal process" paradigm, in which a defined set of target properties will require polyfunctional screening and/or engineering strategies. First attempts at multifunction screening have been reported 47 .
However, despite the recent development of sophisticated molecular engineering and screening technologies, our ability to move around sequence space in search of the ideal catalyst for a given process is still limited. Rational design methods face the greatest limitation in scope. For example, despite the intense focus over the past decade on the molecular determinants of protein stability, sitespecific protein engineering cannot yet be reliably applied to protein stabilization. None of the "design rules" for thermostability that have evolved from comparative structural studies of more and less stable protein homologs 44, 48 can be simply employed to indicate sitespecific modifications for reliably enhancing molecular stability. The use of design algorithms for predicting multiple additive mutations 49 may provide a future guide to the engineering of hyperthermostable enzymes. Such algorithms are not currently available for other functional characteristics (solvent stability, alterations in specificity, pH behavior, or turnover, for example) for which even less generic molecular information is available. Direct (i.e., metagenomic) screening and DNA-shuffling technologies offer the widest access to sequence space. However, both are limited by the fact that any single environmental DNA sample is a poor representation of the enormous genomic diversity present in the multitude of global biotopes. So are we ready to implement the ideal process paradigm? We conclude that many of the necessary molecular and screening technologies are in place, and there is early evidence of an evolution from monofunctional to multifunctional screening. In our opinion, the full implementation of the latter is the key to the successful acquisition of new "designer" biocatalysts for truly optimized "ideal" bioprocesses. a These values are thought to be underestimated, possibly by one to two orders of magnitude. Estimates of accessible species will be proportionally lower.
